Leber Congenital Amaurosis (LCA)
Simulate Leber congenital amaurosis (LCA) — the most severe group of inherited retinal
dystrophies, presenting at birth or within the first year of life with profound visual
impairment, nystagmus, and near-extinguished full-field electroretinogram (ERG).
LCA is genetically heterogeneous, caused by mutations in more than 25 genes
encoding proteins critical to photoreceptor or retinal pigment epithelium (RPE) function:
RPE65 (visual cycle isomerase — LCA2, the first LCA gene approved for gene therapy),
CEP290 (centrosomal protein 290 — LCA10, the most commonly mutated gene,
responsible for ~15–20% of all LCA cases, involving a deep-intronic splicing mutation
c.2991+1655A>G that creates a cryptic exon), GUCY2D (retinal guanylate cyclase 1 —
LCA1, phototransduction cGMP synthesis defect, often with remarkable preservation of
photoreceptor structure despite functional loss), AIPL1 (aryl hydrocarbon receptor
interacting protein-like 1 — LCA4, chaperon for PDE6 assembly), RPGRIP1
(RPGR-interacting protein 1 — LCA6, photoreceptor connecting cilium), and CRB1
(crumbs homologue 1 — LCA8, outer limiting membrane integrity). The Franceschetti
oculo-digital sign (eye poking/pressing) is a classical behavioural feature.
RPE65+associated LCA (LCA2) is the only form with an approved gene therapy:
voretigene neparvovec (LUXTURNA, Spark Therapeutics / Novartis, US FDA approved 2017),
which delivers a functional RPE65 copy to RPE cells via subretinal AAV2 injection,
restoring the visual cycle and enabling meaningful vision improvement.
Model three LCA genetic subtypes: RPE65-associated LCA (visual cycle block,
gene therapy responsive), CEP290/ciliopathy LCA (most common, deep-intronic
mutation, antisense oligonucleotide research), and GUCY2D LCA (phototransduction
cGMP deficit, structurally preserved photoreceptors). Inspect ΔE colour shift,
CIE xy chromaticity, and image-level simulation of severe congenital visual loss.
Leber congenital amaurosis colour science simulation by Auric Artisan.